April 1, 2020
Contact: Sarah Seagraves,
Senior VP for Marketing
(405) 813-2403
[email protected]
Oklahoma City, OK-based Linear Health Sciences has developed a globally patented medical device known as the Orchid Safety Release Valve (SRV), designed to limit disconnection of IV catheters for patients worldwide.
OKLAHOMA CITY — i2E Management Company, Inc. (iMCI), recently led an $11.535 million go-to-market investment in Oklahoma City-based Linear Health Sciences. The investment comes on the heels of continued successes for the Orchid SRV, the company’s flagship medical device designed to reduce accidental IV catheter dislodgement in a novel way.
The iMCI-led investment in Linear Health Sciences includes $2.5 million from Plains Venture Partners I, as well as $1,000,000 from the Accelerate Oklahoma Fund and $500,000 from the Oklahoma Angel Fund II. Plains Venture Partners I, the Accelerate Oklahoma Fund, and the Oklahoma Angel Fund are each managed by iMCI. The remainder of the round was completed by local investors.
The $11.535 million Series B investment round follows a $1.25 million Seed round in 2016 and a $1.54 million Series A in 2018, both led by i2E, Inc., parent company of iMCI.
Co-founded by Oklahoma physician Dr. Ryan Dennis, CEO, and Dan Clark, President, Linear Health Sciences is preparing to launch its globally patented device known as the Orchid Safety Release Valve (SR